Selected research
Industry Research
Cancer Biosimilar Monoclonal Antibodies Industry Research Report 2026
Market perspective
The global Cancer Biosimilar Monoclonal Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cancer Biosimilar Monoclonal Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cancer Biosimilar Monoclonal Antibodies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cancer Biosimilar Monoclonal Antibodies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cancer Biosimilar Monoclonal Antibodies include Innovent Biologics, Teva Pharmaceutical Industries, Sandoz, Sunshine Guojian, Qilu Pharmaceutical, Merck, Mylan, Roche and Junshi Biosciences, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cancer Biosimilar Monoclonal Antibodies market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cancer Biosimilar Monoclonal Antibodies.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Biosimilar Monoclonal Antibodies Market by Company
Innovent Biologics
Teva Pharmaceutical Industries
Sandoz
Sunshine Guojian
Qilu Pharmaceutical
Merck
Mylan
Roche
Junshi Biosciences
Pfizer
Henlius
Biotech Pharma
Bio-Thera Solutions
Amgen
AbbVie
Samsung Bioepis
Celltrion
BristolMyers Squibb
Biocon
Cancer Biosimilar Monoclonal Antibodies Segment by Type
Mouse Derived Monoclonal Antibody
Human Derived Monoclonal Antibody
Human Mouse Chimeric Monoclonal Antibody
Fully Human Derived Monoclonal Antibody
Cancer Biosimilar Monoclonal Antibodies Segment by Application
Hematological System Tumor Treatment
Solid Tumor Treatment
Combination Therapy
Cancer Biosimilar Monoclonal Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biosimilar Monoclonal Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cancer Biosimilar Monoclonal Antibodies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Mouse Derived Monoclonal Antibody
- Human Derived Monoclonal Antibody
- Human Mouse Chimeric Monoclonal Antibody
- Fully Human Derived Monoclonal Antibody
Applications
- Hematological System Tumor Treatment
- Solid Tumor Treatment
- Combination Therapy
Companies covered
- Innovent Biologics
- Teva Pharmaceutical Industries
- Sandoz
- Sunshine Guojian
- Qilu Pharmaceutical
- Merck
- Mylan
- Roche
- Junshi Biosciences
- Pfizer
- Henlius
- Biotech Pharma
- Bio-Thera Solutions
- Amgen
- AbbVie
- Samsung Bioepis
- Celltrion
- BristolMyers Squibb
- Biocon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cancer Biosimilar Monoclonal Antibodies by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Mouse Derived Monoclonal Antibody
- 2.2.3 Human Derived Monoclonal Antibody
- 2.2.4 Human Mouse Chimeric Monoclonal Antibody
- 2.2.5 Fully Human Derived Monoclonal Antibody
- 2.3 Cancer Biosimilar Monoclonal Antibodies by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hematological System Tumor Treatment
- 2.3.3 Solid Tumor Treatment
- 2.3.4 Combination Therapy
- 2.4 Assumptions and Limitations
3 Cancer Biosimilar Monoclonal Antibodies Breakdown Data by Type
- 3.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Type (2021-2026)
- 3.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Type (2027-2032)
4 Cancer Biosimilar Monoclonal Antibodies Breakdown Data by Application
- 4.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Application (2021-2026)
- 4.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cancer Biosimilar Monoclonal Antibodies Market Perspective (2021-2032)
- 5.2 Global Cancer Biosimilar Monoclonal Antibodies Growth Trends by Region
- 5.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Region (2021-2026)
- 5.2.3 Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Region (2027-2032)
- 5.3 Cancer Biosimilar Monoclonal Antibodies Market Dynamics
- 5.3.1 Cancer Biosimilar Monoclonal Antibodies Industry Trends
- 5.3.2 Cancer Biosimilar Monoclonal Antibodies Market Drivers
- 5.3.3 Cancer Biosimilar Monoclonal Antibodies Market Challenges
- 5.3.4 Cancer Biosimilar Monoclonal Antibodies Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cancer Biosimilar Monoclonal Antibodies Players by Revenue
- 6.1.1 Global Top Cancer Biosimilar Monoclonal Antibodies Players by Revenue (2021-2026)
- 6.1.2 Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Players (2021-2026)
- 6.2 Global Cancer Biosimilar Monoclonal Antibodies Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cancer Biosimilar Monoclonal Antibodies Head Office and Area Served
- 6.4 Global Cancer Biosimilar Monoclonal Antibodies Players, Product Type & Application
- 6.5 Global Cancer Biosimilar Monoclonal Antibodies Manufacturers Established Date
- 6.6 Global Cancer Biosimilar Monoclonal Antibodies Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
- 7.2 North America Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
- 7.4 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
- 8.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
- 8.4 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
- 9.2 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
- 10.2 South America Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
- 10.4 South America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
- 11.2 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Innovent Biologics
- 12.1.1 Innovent Biologics Company Information
- 12.1.2 Innovent Biologics Business Overview
- 12.1.3 Innovent Biologics Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.1.4 Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.1.5 Innovent Biologics Recent Developments
- 12.2 Teva Pharmaceutical Industries
- 12.2.1 Teva Pharmaceutical Industries Company Information
- 12.2.2 Teva Pharmaceutical Industries Business Overview
- 12.2.3 Teva Pharmaceutical Industries Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.2.4 Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.2.5 Teva Pharmaceutical Industries Recent Developments
- 12.3 Sandoz
- 12.3.1 Sandoz Company Information
- 12.3.2 Sandoz Business Overview
- 12.3.3 Sandoz Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.3.4 Sandoz Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.3.5 Sandoz Recent Developments
- 12.4 Sunshine Guojian
- 12.4.1 Sunshine Guojian Company Information
- 12.4.2 Sunshine Guojian Business Overview
- 12.4.3 Sunshine Guojian Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.4.4 Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.4.5 Sunshine Guojian Recent Developments
- 12.5 Qilu Pharmaceutical
- 12.5.1 Qilu Pharmaceutical Company Information
- 12.5.2 Qilu Pharmaceutical Business Overview
- 12.5.3 Qilu Pharmaceutical Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.5.4 Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.5.5 Qilu Pharmaceutical Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.6.4 Merck Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Mylan
- 12.7.1 Mylan Company Information
- 12.7.2 Mylan Business Overview
- 12.7.3 Mylan Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.7.4 Mylan Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.7.5 Mylan Recent Developments
- 12.8 Roche
- 12.8.1 Roche Company Information
- 12.8.2 Roche Business Overview
- 12.8.3 Roche Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.8.4 Roche Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.8.5 Roche Recent Developments
- 12.9 Junshi Biosciences
- 12.9.1 Junshi Biosciences Company Information
- 12.9.2 Junshi Biosciences Business Overview
- 12.9.3 Junshi Biosciences Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.9.4 Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.9.5 Junshi Biosciences Recent Developments
- 12.10 Pfizer
- 12.10.1 Pfizer Company Information
- 12.10.2 Pfizer Business Overview
- 12.10.3 Pfizer Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.10.4 Pfizer Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.10.5 Pfizer Recent Developments
- 12.11 Henlius
- 12.11.1 Henlius Company Information
- 12.11.2 Henlius Business Overview
- 12.11.3 Henlius Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.11.4 Henlius Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.11.5 Henlius Recent Developments
- 12.12 Biotech Pharma
- 12.12.1 Biotech Pharma Company Information
- 12.12.2 Biotech Pharma Business Overview
- 12.12.3 Biotech Pharma Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.12.4 Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.12.5 Biotech Pharma Recent Developments
- 12.13 Bio-Thera Solutions
- 12.13.1 Bio-Thera Solutions Company Information
- 12.13.2 Bio-Thera Solutions Business Overview
- 12.13.3 Bio-Thera Solutions Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.13.4 Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.13.5 Bio-Thera Solutions Recent Developments
- 12.14 Amgen
- 12.14.1 Amgen Company Information
- 12.14.2 Amgen Business Overview
- 12.14.3 Amgen Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.14.4 Amgen Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.14.5 Amgen Recent Developments
- 12.15 AbbVie
- 12.15.1 AbbVie Company Information
- 12.15.2 AbbVie Business Overview
- 12.15.3 AbbVie Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.15.4 AbbVie Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.15.5 AbbVie Recent Developments
- 12.16 Samsung Bioepis
- 12.16.1 Samsung Bioepis Company Information
- 12.16.2 Samsung Bioepis Business Overview
- 12.16.3 Samsung Bioepis Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.16.4 Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.16.5 Samsung Bioepis Recent Developments
- 12.17 Celltrion
- 12.17.1 Celltrion Company Information
- 12.17.2 Celltrion Business Overview
- 12.17.3 Celltrion Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.17.4 Celltrion Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.17.5 Celltrion Recent Developments
- 12.18 BristolMyers Squibb
- 12.18.1 BristolMyers Squibb Company Information
- 12.18.2 BristolMyers Squibb Business Overview
- 12.18.3 BristolMyers Squibb Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.18.4 BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.18.5 BristolMyers Squibb Recent Developments
- 12.19 Biocon
- 12.19.1 Biocon Company Information
- 12.19.2 Biocon Business Overview
- 12.19.3 Biocon Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2021-2026)
- 12.19.4 Biocon Cancer Biosimilar Monoclonal Antibodies Product Portfolio
- 12.19.5 Biocon Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst